A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.

Also called NCT07239570

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 125 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07239570
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Germany, Spain, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07239570. Randomized; no masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2028-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
Acronym
CKD-bioMatch
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Semaglutide
Intervention (Drug)
Finerenone
Lead sponsor
Peter Rossing (class: other)
Collaborator
University Medical Center Groningen (class: other)
Collaborator
Lund University (class: other)
Collaborator
Instituto de Investigacion Sanitaria INCLIVA (class: other)
Collaborator
Universitätsklinikum Hamburg-Eppendorf (class: other)

Record details

Record id
cardio:ct-nct07239570
Content hash
91119ecec080389a86e7859d1f8eb3693d9266b54c8df84a6e04c8843f42d28a